Profile for South Korea Patent: 20250150154

US Patent Family Members and Approved Drugs for South Korea Patent: 20250150154

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
11,154,521	Oct 17, 2036	Acer	OLPRUVA	sodium phenylbutyrate
11,202,767	Oct 17, 2036	Acer	OLPRUVA	sodium phenylbutyrate
11,433,041	Oct 17, 2036	Acer	OLPRUVA	sodium phenylbutyrate

Key insights for pharmaceutical patentability - South Korea patent KR20250150154

Last updated: April 23, 2026

South Korea Patent KR20250150154: Scope, Claim Set, and Landscape Map

What does KR20250150154 claim?

No analysis can be produced because the patent text (claims, specification, and claim numbering) is not present in the provided input, and the scope and landscape require claim-by-claim parsing tied to the official publication and/or granted record.

What is the scope of protection in KR20250150154?

A scope assessment requires at minimum:

• independent claim language (including all limitations)
• dependent claim structure and all dependency mappings
• defined terms (drug name, salt/solvate forms, polymorphs, dosing regimens, compositions, use claims, and manufacturing limitations)
• claim status and procedural posture (application vs grant)

Those elements are not available in the supplied content, so no compliant, accurate scope statement can be generated.

How does KR20250150154 position against existing KR and global filings?

A patent landscape requires:

• bibliographic identifiers (assignee, priority, publication date)
• family members and equivalents (WO/EP/US/CN/JP where applicable)
• citations and examiner references
• active or expired status across relevant jurisdictions

None of that bibliographic or family data is included, so no landscape can be constructed without fabricating.

---

Key Takeaways

• KR20250150154 scope and claim coverage cannot be analyzed from the provided input because the patent’s claim text and legal status data are not included.
• A reliable KR and global landscape cannot be mapped without bibliographic details, family linkage, and the claim set.

---

FAQs

1. Can you summarize the independent claim limitations of KR20250150154?
   Not from the provided input because the claims are not included.

2. Which dependent claims define composition versus method-of-use coverage?
   Not determinable because the dependent claim text is not provided.

3. Does KR20250150154 cover salts, polymorphs, or specific formulations?
   Not determinable because definition and claim language are not provided.

4. What earlier patents or cited documents impact novelty and inventive step?
   Not determinable because the citation list and examiner record are not provided.

5. How does KR20250150154 affect market exclusivity in South Korea?
   Not determinable because validity/grant status, term, and linkage status are not provided.

---

References

1. (No sources were provided in the prompt to cite.)